Oncolytics Biotech announces clinical supply agreement to evaluate pelareorep with Loqtorzi in anal cancer

ONCY•2026-11-11

Oncolytics Biotech announced a clinical supply agreement to evaluate pelareorep with Loqtorzi in squamous cell anal carcinoma, with the study expected to begin in the U.S. in Q1 2027.

1. Planned study

Oncolytics Biotech announced a clinical supply agreement to evaluate pelareorep in combination with Loqtorzi (toripalimab-tpzi) in squamous cell anal carcinoma. The study is expected to begin in the U.S. in Q1 2027.

Oncolytics Biotech announces clinical supply agreement to evaluate pelareorep with Loqtorzi in anal cancer

1. Planned study

Related News

Vylor Q3 pro forma loss from continuing operations widens 23% to $480 million

Guardant Health announces proposed $500 million convertible notes offering due 2032

RLI declares regular and special dividends

Senstar Technologies publishes Q3 2026 earnings call transcript

Tennessee American Water applies $13.07 PFAS settlement credit, total refunds over $84 per customer